<DOC>
	<DOCNO>NCT02972905</DOCNO>
	<brief_summary>GSK2269557 potent highly selective inhale Phosphoinositide 3-Kinase ( PI3K ) delta inhibitor develop anti-inflammatory anti-infective agent treatment inflammatory airway disease , chronic obstructive pulmonary disease ( COPD ) . The purpose study assess safety , tolerability pharmacokinetics ( PK ) single repeat dos GSK2269557 administer via ELLIPTA dry powder inhaler ( DPI ) healthy Japanese subject . This first time Japanese subject GSK2269557 administer via ELLIPTA DPI addition magnesium stearate . In group study , subject receive single dose either GSK2269557 placebo Session 1 receive daily dose GSK2269557 placebo 10 day Session 2 . Session 1 next dose strength may run parallel Session 2 previous dose . The dos plan study 200 microgram ( mcg ) , 500 mcg 700 mcg . There least 10 day washout two dose session . Follow period start 10 day ( +-1 day ) last dose Session 2 . A total number 36 subject enrol study 27 subject receive dose strength GSK2269557 9 subject receive dose strength GSK2269557 . ELLIPTA trademark GSK group company .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability Pharmacokinetics GSK2269557 Japanese Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Inclusion Criteria Participant must 20 64 year age inclusive , time signing informed consent . Participants overtly healthy determine medical evaluation include medical history , physical examination , laboratory test , ECG . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator consultation Medical Monitor require agree find unlikely introduce additional risk factor interfere study procedure . Normal spirometry ( forced expiratory volume 1 second &gt; =80 % predict ) Screening . Body weight &gt; =50 kilogram ( kg ) body mass index ( BMI ) within range 18.5 24.9 kg/square meter ( m^2 ) ( inclusive ) . Japanese Male : A male participant must agree use contraception protocol treatment period follow visit . Capable give sign informed consent describe restriction list informed consent form ( ICF ) . Exclusion Criteria History presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study treatment ; interfere interpretation data Abnormal blood pressure determine investigator ALT &gt; 1.5x upper limit normal ( ULN ) Bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) QTcF &gt; 450 millisecond ( msec ) . Past intend use overthecounter prescription medication include herbal medication within 14 day prior dose . History donation blood blood product &gt; =400 milliliter ( mL ) within 3 month &gt; =200 mL within 1 month prior screen Exposure 4 new chemical entity within 12 month prior first dose day Current enrollment past participation within last 30 day sign consent clinical study involve investigational study treatment type medical research The subject positive Serological test syphilis ( rapid plasma reagin Treponema pallidum ) , Human immunodeficiency virus ( HIV ) Antigen/Antibody , Hepatitis B surface antigen ( HbsAg ) , Hepatitis C virus ( HCV ) antibody , Human Tcell lymphotropic virus type 1 ( HTLV1 ) antibody screen . Positive prestudy drug screen Regular use know drug abuse Regular alcohol consumption within 6 month prior study define : average weekly intake &gt; 14 unit male . One unit equivalent 350 ml beer , 150 ml wine 45 ml 80 proof distil spirit Smoking history regular use tobacco nicotinecontaining product within 6 month prior screen Sensitivity study treatment , component thereof , drug allergy , opinion investigator medical monitor , contraindicate participation study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>GSK2269557</keyword>
	<keyword>Dry powder Inhaler ( DPI )</keyword>
	<keyword>tolerability</keyword>
	<keyword>safety</keyword>
	<keyword>ELLIPTA</keyword>
</DOC>